Document is current
Any future updates will be listed below
-
Authors
Ferrari-Souza, João Pedro https://orcid.org/0000-0003-2183-1551
Povala, Guilherme https://orcid.org/0000-0002-2023-6569
Rahmouni, Nesrine
Bellaver, Bruna https://orcid.org/0000-0002-2212-3373
Ferreira, Pamela C. L. https://orcid.org/0000-0003-2134-9829
De Bastiani, Marco Antônio
Leffa, Douglas T. https://orcid.org/0000-0002-4890-8451
Lussier, Firoza Z.
Aguzzoli, Cristiano S. https://orcid.org/0000-0002-7378-3830
Brum, Wagner S.
Carello-Collar, Giovanna
Borelli, Wyllians V.
Therriault, Joseph
Macedo, Arthur C.
Servaes, Stijn
Stevenson, Jenna
Pola, Ilaria
Gauthier, Serge
Souza, Diogo O.
Schilling, Lucas Porcello
Lourenco, Mychael V. https://orcid.org/0000-0002-1078-0296
Triana-Baltzer, Gallen
Kolb, Hartmuth C.
Benedet, Andréa L.
Ashton, Nicholas J.
Tudorascu, Dana L.
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Johnson, Sterling C. https://orcid.org/0000-0002-8501-545X
Pascoal, Tharick A. https://orcid.org/0000-0001-9057-8014
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Zimmer, Eduardo R. https://orcid.org/0000-0002-5349-0053
- License Information
-
More Information
Article History
Received: 30 September 2024
Accepted: 24 September 2025
First Online: 6 November 2025
Competing interests
: W.V.B. served as a speaker for Novo Nordisk. J.T. has received personal fees from Alzheon and Neurotorium (outside the submitted work). S.G. is acting as scientist advisor to AmyriAD, Enigma USA, Eisai Canada, Lilly Canada, Novo Nordisk Canada and TauRx and is editor-in-chief of the Journal of Prevention of Alzheimer ʼs Disease . L.P.S. has participated in educational activities organized by Aché, Apsen, Biogen, Knight, Libbs, Lilly, Novo Nordisk and Roche and has served on advisory boards for Biogen, Knight, Lilly, Novo Nordisk and Roche. G.T.-B. is an employee of Johnson & Johnson. H.C.K. was an employee of Johnson & Johnson at the time this work was performed. N.J.A. has given lectures in symposia sponsored by Lilly and Quanterix. H.Z. has served on scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program (outside the submitted work). K.B. has served as a consultant and on advisory boards for AbbVie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharmaceutical, Prothena, Roche Diagnostics and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program (outside the submitted work). S.C.J. serves on advisory boards for ALZPath, Enigma Biomedical, Alamar, Lilly and Merck. E.R.Z. has served on scientific advisory boards, as a consultant or as a speaker for Nintx, Novo Nordisk, Biogen, Lilly and Magdalena Biosciences; he is also a co-founder and minority shareholder of masima. The other authors declare no competing interests.
